Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?

Transplantation Reviews

Volumn 23, Issue 1, 2009, Pages 47-52

  Nashan, Björn ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; IMMUNOMODULATING AGENT; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; THROMBOSIS;

EID: 56249092773     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2008.08.005     Document Type: Article

References (37)

1. Meier-Kriesche H.-U., Li S., Gruessner R.W.G., et al. Immunosuppression: evolution in practice and trends 1994-2004. Am J Transplant 6 (2006) 1111-1131
2. Flechner S.M., Kobashigawa J., and Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 22 (2008) 1-15
3. Shapiro R., Young J.B., Milford E.L., et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 5 (2005) 874-886
4. Webster A.C., Woodroffe R.C., Taylor R.S., et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. Br Med J 331 (2005) 810-820
5. Vincenti F., Friman S., Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7 (2007) 1506-1514
6. Silva H.T., Yang H.C., Abouljoud M., et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 7 (2007) 595-608
7. Pirsch J.D., Miller J., Deierhoi M.H., et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 7 (1997) 977-983
8. Mayer A.D., Dmitrewski J., Squifflet J.P., et al. Multicenter randomised trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 64 (1997) 436-443
9. Cole E.H., Johnston O., Rose C., et al. PTDM and acute rejection are associated with a similar risk for graft loss [abstract]. Am J Transplant 7 Suppl 2 (2007) 150
10. Kaplan B., Schold J., and Meier-Kriesche H.U. Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 14 (2003) 2980-2984
11. Meier-Kriesche H.-U., Schold J.D., Srinivas T.R., et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004) 378-383
12. McDonald S., Russ G., Campbell S., et al. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant 7 (2007) 1201-1208
13. Margreiter R., and for the European Tacrolimus vs Ciclosporin Microemulsion Rental Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 359 (2002) 741-746
14. Trompeter R., Filler G., Webb N.J., et al. Randomized trial of tacrolimus versus cyclosporine microemulsion in renal transplantation. Pediatr Nephrol 17 (2002) 141-149
15. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357 (2007) 2562-2575
16. Laskow D.A., Vincenti F., Neylan J., et al. Phase II FK 506 multicenter concentration control study: one-year follow-up. Transplant Proc 27 (1995) 809-811
17. Johnson C., Ahsan N., Gonwa T., et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69 (2000) 834-841
18. Campos H., and Filho M. One-year follow-up of a Brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation. Transplant Proc 34 (2002) 1656-1658
19. Egfjord M., Ladefoged J., and Olgaard K. Similar frequency of acute rejection, graft and patient survival in quadruple therapy with tacrolimus versus cyclosporin in combination with prednisone, mycophenolate mofetil, and atgam after renal allotransplantation [abstract]. XIXth International Congress of the Transplantation Society, Miami, Fl, 2530 August (2002)
20. Wang X.H., Tang X.D., and Xu D. Tacrolimus vs CyA Neoral in combination with MMF and steroids after cadaveric renal transplantation. Transplant Proc 32 (2000) 1702-1703
21. Yang H.C., Holman M.J., Langhoff E., et al. Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation-1-year follow-up of a prospective, randomized clinical trial. Transplant Proc 31 (1999) 1121-1124
22. Charpentier B., Rostaing L., Berthoux F., et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 75 (2003) 844-851
23. Solez K., Vincenti F., and Filo R.S. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 66 (1998) 1736-1740
24. Rowshani A.T., Scholten E.M., Bemelman F., et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 17 (2006) 305-312
25. Nankivell B.J., Borrows R.J., Fung C.L.S., O'Connell P.J., Allen R.D.M., and Chapman J.R. The natural history of chronic allograft nephropathy. New Eng J Med 349 (2003) 2326-2333
26. Ekberg H., Tedesco-Silva H., Demirbas A., et al. CNI sparing in de novo renal transplantation: 3-year results from the Symphony study. Am J Transplant 8 Suppl 2 (2008) Abstract LB04
27. Kaplan B., Schold J., and Meier-Kriesche H.-U. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 3 (2003) 1560-1565
28. McEwan P., Baloobal K., Dizon S., Conway P., and Currie C.J. Patterns of graft and patient survival following renal transplantation and evaluation of serum creatinine as a predictor of graft survival: a review of data collected from one clinical centre over 34 years. Curr Med Res Opin 21 (2005) 1793-1800
29. Hariharan S., McBride M.A., Cherikh W.S., et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kid Int 62 (2002) 311-318
30. Kasiske B.L., Andany M.A., Hernandez D., et al. Comparing methods for monitoring serum creatinine to predict late renal allograft failure. Am J Kidney Dis 38 (2001) 1065-1073
31. Goldfarb-Rumyantzev A.S., Smith S., Shihab F.S., et al. Role of maintenance immunosuppressive regimen in kidney transplant outcome. Clin J Am Soc Nephrol 1 (2006) 563-574
32. Bunnapradist S., Peng A., Fukami S., et al. Renal allograft outcomes according to initial immunosuppressive regimen: a five year follow-up of OPTN database. Am J Transplant 5 Suppl 11 (2005) 251
33. Woodward R.S., Kutinova A., Schnitzler M.A., et al. Renal graft survival and calcineurin inhibitor. Transplantation 80 (2005) 629-633
34. Habib A.N., Smith L., Barenbaum L.L., et al. The role of maintenance immunosuppressive regimen in long term kidney transplant outcome. Am J Transplant 5 Suppl 11 (2005) 465
35. Irish W., Sherrill B., Brennan D.C., et al. Three year posttransplant survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple drug regimen. Transplantation 76 (2003) 1686-1690
36. Bechstein W.O., Malaise J., Saudek F., et al. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. Transplantation 77 (2004) 1221-1228
37. Saudek F, Malaise J, Boucek P, et al. for the Euro-SPK Study Group. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. Nephrol Dial Transplant 2005;20(Suppl 2):ii3-10, ii62.